摘要
本研究利用gpt筛选基因和eGFP报告基因纯化筛选重组小反刍兽疫病毒(PPRV)F基因的重组山羊痘病毒(rGPV-PPRV-F),并经过PCR鉴定。免疫荧光和蛋白印迹试验都证实重组病毒能够感染绵羊羔羊睾丸细胞并表达PPRVF蛋白。以2×106PFU的rGPV-PPRV-F皮内注射免疫山羊3只,并于首次免疫后第28d以相同剂量进行二次免疫。分别于一免后21d和二免后14d采血后分离血清进行病毒中和试验。结果表明,一免后21d山羊痘病毒(GPV)中和抗体效价依次为1∶40、≥1∶80、≥1∶80,PPRV中和抗体效价依次别为1∶20、1∶40、1∶20,全部阳转;二免后14d,GPV中和抗体效价≥1∶80,PPRV中和抗体效价依次为1∶20、1∶80、1∶40。本研究为小反刍兽疫重组山羊痘疫苗的产业化奠定了基础。
To evaluate the immune effectiveness of the recombinant goat pox virus (GPV) containing PPRV F gene (rGPV- PPRV-F), three goats was immunized with 2 ×10^6 PFU rGPV-PPRV-F through intradermal injection, and boosted at 28 d post first immunization with the same dosage of recombinant virus. Serum was collected after immunization for antibody analysis against GPV and PPRV. Neutralization antibody against goat pox virus and PPRV were 1:40 to 1:80 and 1:20 to 1:40, respectively at 21 d after first immunization, and increased up to 1:80 at 14 d post second immunization. This study established the foundation for the development of a bivalent recombinant vaccine against PPRV and goat pox virus.
出处
《中国预防兽医学报》
CAS
CSCD
北大核心
2009年第6期415-420,共6页
Chinese Journal of Preventive Veterinary Medicine
基金
国家863计划(20060102Z449)